Clinical Trials Logo

Juvenile Xanthogranuloma (JXG) clinical trials

View clinical trials related to Juvenile Xanthogranuloma (JXG).

Filter by:
  • None
  • Page 1

NCT ID: NCT06153173 Recruiting - Clinical trials for Histiocytic Disorders

Mirdametinib in Histiocytic Disorders

Start date: February 5, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.

NCT ID: NCT02285582 Active, not recruiting - Clinical trials for Juvenile Xanthogranuloma (JXG)

International Rare Histiocytic Disorders Registry (IRHDR)

IRHDR
Start date: October 2014
Phase:
Study type: Observational [Patient Registry]

The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease that resolves spontaneously, to progressive disseminated forms that can be sometimes life-threatening. Since they are extremely rare, there is limited understanding of their causes and best treatment options. Physicians, patients and parents of children with RHDs frequently consult members of the Histiocyte Society regarding the best management of these disorders. Very often, no specific recommendation can be made due to the lack of prospective outcome data, or even large retrospective case series. The creation of an international rare histiocytic disorders registry (IRHDR) could facilitate a uniform diagnosis of the RHDs, as well as the collection and analysis of the clinical, epidemiological, treatment and survival data of patients with RHD. The registry may also lead to future therapeutic recommendations, provide a framework for future clinical trials and create excellent research opportunities.